Hanmi Pharmaceutical Maintains ... > 경제기사 | economics

Hanmi

[Alpha Biz= Reporter Kim Jisun] Hanmi Pharmaceutical will continue under the leadership of current CEO Jae-Hyun Park after the board rejected a proposal to appoint Im Jong-yoon, the eldest son of the group’s founder, as the new CEO.
On September 2, the board of directors convened at Hanmi Pharmaceutical’s headquarters in Bangi-dong, Songpa-gu, Seoul, to discuss the nomination of Executive Director Im Jong-yoon as the new CEO. However, the proposal was voted down. Additionally, a proposal to replace the chairman of Beijing Hanmi Pharmaceutical and appoint new directors, which was also suggested by Im, was rejected. All ten board members, including CEO Park and Director Im, were present at the meeting.

With CEO Park retaining his position, Hanmi Pharmaceutical is set to continue its independent management strategy. Last month, Park established new HR and legal teams within Hanmi Pharmaceutical, emphasizing that the company would operate independently from its parent company, Hanmi Science.

Hanmi Pharmaceutical plans to gradually establish additional departments necessary for its independent management moving forward.


관련기사

▶ [경제용어 나들이] 경기동향지수가 뭘까요? : 경제용어사전｜알파경제TV

▶ ‘반도체 전쟁’ 인재 확보 총력전…SK하이닉스, 2개월만 또 다시 채용

▶ 유정현 넥슨 총수일가, 2여년만 상속세 5조3000억원 조기납부 완료

▶ 새 출범한 SK스피드메이트 AI 기반 자동차 애프터마켓 선도

▶ [마감] 코스피, 7거래일 만에 돌아온 外人에 0.25% 상승한 2681 마감

/ 알파경제 Kim Jisun Reporter